Showing 1 - 5 results of 5 for search 'Tomas Buchler', query time: 0.03s Refine Results
  1. 1
    Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer

    Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer by Eva Streckova, Jiri Stejskal, Daniela Kuruczova, Adam Svobodnik, Radka Stepanova, Tomas Buchler

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab

    The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab by Ondrej Fiala, Pavel Pitule, Petr Hosek, Vaclav Liska, Ondrej Sorejs, Jan Bruha, Ondrej Vycital, Tomas Buchler, Alexandr Poprach, Ondrej Topolcan, Jindrich Finek

    Published 2017-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Association of the combined parameters including the frequency of primary cilia, PD-L1, Smoothened protein, membranous β-catenin and cytoplasmic β-catenin expression with the outcome of patients with clear cell renal cell carcinoma

    Association of the combined parameters including the frequency of primary cilia, PD-L1, Smoothened protein, membranous β-catenin and cytoplasmic β-catenin expression with the outco... by Aneta Rozsypalova, Blanka Rosova, Alzbeta Filipova, Dimitar Hadzi Nikolov, Renata Chloupkova, Igor Richter, Roman Zachoval, Radoslav Matej, Bohuslav Melichar, Tomas Buchler, Josef Dvorak

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study

    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study by Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, Maria T. Bourlon, Ravindran Kanesvaran, Umberto Basso, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Zin W. Myint, Giuseppe Fornarini, Thomas Buttner, Se Hoon Park, Yüksel Ürün, Ugo De Giorgi, Renate Pichler, Pasquale Rescigno, Tomas Buchler, Hana Studentova, Bohuslav Melichar, Jawaher Ansari, Veronica Mollica, Jakub Kucharz, Mimma Rizzo, Alessandro Rizzo, Ray Manneh Kopp, Sebastiano Buti, Fernando Sabino Marques Monteiro, Andrey Soares, Aristotelis Bamias, Matteo Santoni

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

    Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) by Matteo Santoni, Giandomenico Roviello, Enrique Grande, Ugo De Giorgi, Ondrej Fiala, Emmanuel Seront, Javier Molina-Cerrillo, Renate Pichler, Zin W. Myint, Jakub Kucharz, Ravindran Kanesvaran, Thomas Büttner, Martin Pichler, Umberto Basso, Jindrich Kopecky, Maria T. Bourlon, Linda Cerbone, Tomas Buchler, Alvaro Pinto, Alfonso Gómez de Liaño, Caterina Gianni, Anca Zgura, Pasquale Rescigno, Jawaher Ansari, Orazio Caffo, Zsófia Küronya, Maria Giuseppa Vitale, Dipen Bhuva, Martina Catalano, Nuno Vau, Ray Manneh Kopp, Sebastiano Buti, Aristotelis Bamias, Camillo Porta, Kaisa Sunela, Francesco Massari

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: